Arbutus Biopharma
Arbutus scraps COVID-19 and RNA degradation programs after disappointing preclinical results
Anika Sharma
Arbutus Biopharma has made significant strategic shifts by discontinuing its involvement in COVID-19 research and RNA destabilizer programs, redirecting its ...
